
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Eric Simpson explains how both clinical and subclinical disease control are critical for achieving true disease modification in atopic dermatitis, emphasizing the role of biomarkers in predicting long-term outcomes and guiding treatment decisions.
Learn about the multifaceted burden of uncontrolled pediatric asthma on patients and their caregivers.
Join Dr. Miguel Lanz as he explains the clinical utility of FeNO as a biomarker of severe asthma.
Join Professors Jean-David Bouaziz, Amy Paller, and Alan Irvine for a dynamic presentation on the multifaceted burden of atopic dermatitis, the evolving concept of disease modification, and how targeted systemic therapies may help improve long-term patient outcomes.

Dr. Eugene Bleecker presents the utility of FeNO as a biomarker of type 2 inflammation and its role in the disease burden of asthma.

Dr. Jonathan Corren describes the diagnostic, predictive, and prognostic role of IgE as a biomarker of type 2 inflammation in asthma.

Dr. Elliot Israel presents the utility of eosinophils as a biomarker of type 2 inflammation and their role in the disease burden of asthma.
Drs. Stephen I. Rennard and Igor Barjaktarevic discuss the diverse clinical aspects of COPD, emphasizing the role of inflammation and the importance of recognizing the heterogeneity of COPD.
Learn how to identify chronic obstructive pulmonary disease (COPD) patients with type 2 inflammation using blood eosinophil (EOS) levels, understand the associated risks, and recognize factors that may influence EOS counts.

Explore 3 hypothetical patient cases using guideline-based checklists for assessment and diagnosis of type 2 inflammation in adult asthma.
Explore the concept of disease modification in atopic dermatitis through this interactive infographic, which highlights potential considerations such as optimal sustained disease control, subclinical inflammation, the pathophysiology of AD, and atopic/non-atopic comorbidities.